Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: Results of four multicenter, double-blind, randomized phase II studies

Journal of Oncology Practice

Volumn 6, Issue 3, 2010, Pages 133-140

  Burris III, Howard A ^a   Belani, Chandra P ^a   Kaufman, Peter A ^a   Gordon, Alan N ^a   Schwartzberg, Lee S ^a   Paroly, Warren S ^a   Shahin, Seta ^a   Dreiling, Lyndah ^a   Saven, Alan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ALLERGIC PNEUMONITIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCYTOPENIA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

EID: 77956111103     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.091094     Document Type: Article

References (23)

1. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266, 2006
2. Link BK, Budd GT, Scott S, et al: Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: Current patterns of care. Cancer 92:1354-1367, 2001
3. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
4. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
5. Molineux G, Dexter TM: Biology of G-CSF, in Morstyn G, Dexter TM, Foote M (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice (ed 2). New York, NY, Informa Healthcare, 1998, pp 51-71, 606-607
6. Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002
7. Green MD, Koelbl H, Baselga J, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35, 2003
8. Amgen: Neulasta prescribing information. http://www.neulasta.com/pdf/ Neulasta-PI.pdf
9. Meropol NJ, Miller LL, Korn EL, et al: Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 84:1201-1203, 1992
10. Rowinsky EK, Grochow LB, Sartorius SE, et al: Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 14:1224-1235, 1996
11. Ottmann OG, Hoelzer D, Gracien E, et al: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 86:444-450, 1995
12. Weiss AJ, Lackman RD: Infusional chemotherapy combined with human granulocyte colony-stimulating factor: Advantages and limitations. Am J Clin Oncol 20:63-68, 1997
13. Weiss AJ, Sabol J, Lackman RD: Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: An effective method of increasing dose intensity. Am J Clin Oncol 22:38-41, 1999
14. Geissler K, Koller E, Hubmann E, et al: Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia: A randomized phase-III study. Blood 90:590-596, 1997
15. Ellis G, Green S, Livingston R, et al: Neoadjuvant doxorubicin, cyclophosphamide and G-CSF (AS+G) for locally advanced breast cancer (LABC), a Southwest Oncology Group phase II study. Proc Am Soc Clin Oncol 19:85a, 2000 (abstr 326)
16. Whitworth JM, Matthews KS, Shipman KA, et al: The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601-604, 2009
17. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
18. Hughes WT, Armstrong D, Bodey GP, et al: Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002
19. Blackwell S, Crawford J: Filgrastim (r-metHuG-CSF) in the chemotherapy setting, in Morstyn G, Dexter TM (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, NY, Marcel Dekker, 1994, pp 103-116
20. Lyman GH, Morrison VA, Dale DC, et al: Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymph 44:2069-2076, 2003
21. Nabholtz JM, Cantin J, Chang J, et al: Randomized double-blind phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide: Results of the BCIRG004 trial. Clin Breast Cancer 3:268-275, 2002
22. National Comprehensive Cancer Network: Practice Guidelines in Oncology - Myeloid Growth Factors. http://www.nccn.org/professionals/physician-gls/PDF/ myeloid-growth.pdf
23. Smith TJ, Khatcheressian J, Lyman GH, et al: Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006